I am Biotech
Science for Life The Biotechnology Innovation Organization (BIO) is the world’s largest biotechnology trade association.
BIO is a 501(c)(6) non-profit organization headquartered in Washington, D.C. We provide advocacy, business development, and communications services for more than 1,100 members worldwide. It is our mission to be the champion of biotechnology and the advocate for our member organizations - both large and small. Our members - many of whom are small emerging companies - are involved in the research an
CAR-T cell therapy is revolutionizing personalized treatment - but bringing it out of academic centers and into communities requires education, infrastructure, and commitment. Hear from Lynelle Hoch, President of Cell Therapy Organization at Bristol Myers Squibb, and other industry leaders on what that looks like in practice.
Read more on Bio.News:
https://bio.news/bio-convention/bio-2026-realizing-the-promise-of-car-t-cell-therapies/
07/31/2026
In a recent report, Magnolia Market Access looks at the compounding effect of NIH funding instability, FDA challenges, and evolving pricing policies and their collective impact on investment, development timelines, and the future pipeline of medicines and cures. Learn more: https://www.magnoliamarketaccess.com/insight/us-biopharmaceutical-innovation-ecosystem-at-risk/
At , we asked Herb Sarnoff, Founder & CEO of iNFixion Bioscience, what drives him. As a parent of a child with neurofibromatosis (NF1), his answer is deeply personal.
Save the date for in Philadelphia, June 7-10. convention.bio.org
Our second annual AI Summit explored where AI is already delivering results in biotech - and what companies need to do to unlock its full potential.
What does meaningful AI adoption in biotech actually look like? Read more on Bio.News.
may be behind us, but an innovator’s drive never leaves. While in San Diego, we asked Nolan Townsend, CEO of Lexeo Therapeutics, what drives him.
Save the date for in Philadelphia, June 7-10. convention.bio.org
BiotechTV's inaugural U.S. Science Summit brought together some of the best science communicators, storytellers, and biotech leaders for a day of real collaboration and learning.
Thank you to Biotechtv , MassBio , Brad Loncar, Chloe Kirk, and every communicator and leader in the room. The future of science depends on how well we tell its story - and this week showed why.
A proposed OMB rule to regulate federal grants could have far-reaching consequences for the biomedical research ecosystem - from academic institutions to private-sector investment and the development of new therapies. BIO has submitted formal comments urging OMB to reconsider.
What would disruptions to federal funding mean for the future of U.S. biotech innovation? Read more on Bio.News: https://bio.news/latest-news/bio-expresses-concerns-over-proposed-omb-rule-to-regulate-federal-grants/
07/16/2026
BIO is pleased to welcome several newly elected members to our Board of Directors. At a critical moment for the industry, their leadership will help advance our mission to protect patient access, defend the innovation ecosystem, and cement biotech’s role as a cornerstone of America’s health, economic, and national security.
Please join us in welcoming the newest members of BIO’s Board:
- Lisa French, Executive Vice President & Chief Commercial Officer, Keenova
- Chirfi Guindo, Executive Vice President, Strategic Access, Policy and Communications, Merck
- Will Lewis, Chair and Chief Executive Officer, Insmed Incorporated
- Jason Marks, Chief Strategy and Chief Legal Officer, BridgeBio
- Alex Sapir, President & CEO, Fulcrum Therapeutics
- Chris Senner, Executive Vice President and Chief Financial Officer, Exelixis
- Richard Staub, President, R&D Solutions, IQVIA
: Bio.News recently covered a new report from Magnolia Market Access that highlights how pressures on research funding, regulatory capacity, and investment incentives are slowing innovation and threatening the pipeline of future medicines.
As the report shows, these policies don’t exist in isolation, and their combined effect is what puts long-term innovation at stake.
Read more: https://bio.news/health/as-policy-ecosystem-threatens-biotech-new-treatments-could-drop-by-over-50-in-20-years/
From a record-breaking 70,000+ meetings across the exhibition floor to dynamic networking moments and interactive activations - including the ever-energized World Cup Lounge - showcased the power of coming together to accelerate innovation. Thank you to the biotech community - from innovators and industry partners to patient advocates, researchers, and scientists - who came together to make this year’s Convention an unforgettable four days of connection and collaboration, and for creating a palpable energy and excitement that will drive our momentum forward.
As we celebrated 50 years of modern biotechnology - pioneered in California - we reflected on how far the industry has come, and more importantly, where it’s headed. Throughout all four days, leaders explored the forces shaping the next decade of discovery: from AI-driven breakthroughs and biodefense and national security to advancing a science-based policy and regulatory ecosystem that enables innovation to thrive.
Beyond the stage, attendees engaged in hands-on learning through BIO Business Solutions® and professional development courses, gaining practical insights from industry experts and investing in the skills that will drive the next generation of breakthroughs.
At every turn, one theme was clear: this global community is driven by purpose - to turn scientific possibility into real-world impact.
As we look ahead to BIO 2027 in Philadelphia, sign up for event updates and be the first to know what’s next: convention.bio.org
Click here to claim your Sponsored Listing.